

## **AABB THOR Joint Working Group**

## CHAIR:

PURPOSE: Identify joint opportunities to advance transfusion medicine clinical practice, support innovation of new

products, and further knowledge transfer to reduce the risk of death from hemorrhagic shock due to all

ctiologic

CHARGES: 1. Develop a prioritized agenda of issues, opportunities, and positions that AABB could pursue as it works in collaboration with the THOR Network. (Possible issues include: range of clinical practice, data collection needs, product development, product use, standards review and advocacy agenda considerations

as it relates to transfusion medicine within the civilian and military care settings)

2. Identify data platforms to capture the epidemiology, practice patterns and outcomes for transfused patients.

- 3. Evaluate the need for uniform titer method and /or options for use of "low titer" blood products.
- 4. Review existing AABB BBTS standards and identify standards that are of concern and the need for revision. Provide data, if available and recommend that standards be reviewed for possible revision.
- 5. Develop proposal for position development and/or an advocacy agenda associated with emergency preparedness in conjunction with the THOR Network.
- 6. Propose Educational Programs for AM, e-casts and a pre AM program.
- 7. Working with the Regulatory and Policy Departments, liaison with FDA regarding Review/Assessment of licensing criteria used by FDA needed for platelet products when indicated for patients with bleeding and new storage solutions for whole blood.

## Current Personnel as of May 08, 2024

Name	Roles
<u>Co-Chair</u>	
Mark Yazer	
Philip C. Spinella, MD	
<u>Member</u>	
Dr. James Stubbs	
Dr. Andrew Peter Cap	
Dr Steven Sloan	
Dr Paul Ness	
Kevin Ward, MD	
Donald Jenkins, MD	
Prof. Eilat Shinar	
Dr. Torunn Apelseth	
Dr Nancy Dunbar	
Jeremy Cannon	
Staff Liaison	
Sharon Carayiannis	



**Time Commitment:**